Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Librofem 200mg tablets
1001010J0BSAAAD
|
Librofem | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Lioresal Intrathecal 10mg/20ml inf ampoules
1002020C0BBAGA4
|
Lioresal | Baclofen | Musculoskeletal and Joint Diseases | No data available |
|
Lioresal Intrathecal 10mg/5ml solution for infusion ampoules
1002020C0BBAFA3
|
Lioresal | Baclofen | Musculoskeletal and Joint Diseases | No data available |
|
Lioresal Intrathecal 50micrograms/1ml inj ampoules
1002020C0BBAEA2
|
Lioresal | Baclofen | Musculoskeletal and Joint Diseases | No data available |
|
Lloydspharmacy Ibuprofen 100mg/5ml oral suspension
1001010J0CMAFBH
|
Lloydspharmacy (Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Lloydspharmacy Ibuprofen 200mg liquid capsules
1001010J0CMADAA
|
Lloydspharmacy (Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Lloydspharmacy Ibuprofen Long Lasting 200mg capsules
1001010J0CMACBA
|
Lloydspharmacy (Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Lloydspharmacy Maximum Strength Ibuprofen 10% gel
1003020P0BRAAAI
|
Lloydspharmacy (Topical Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Lloydspharmacy Maximum Strength Ibuprofen 400mg liq caps
1001010J0CMAEAU
|
Lloydspharmacy (Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Lloydspharmacy Vapour Rub
1003020N0BPABA0
|
Lloydspharmacy Rub | Methyl salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid 25mg gastro-resistant tablets
1001010C0BRABAD
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid 50mg gastro-resistant tablets
1001010C0BRAAAE
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid Retard 100 tablets
1001010C0BRADAF
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid Retard 75 tablets
1001010C0BRACAL
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lornoxicam 4mg tablets
1001010AIAAABAB
|
Lornoxicam | Lornoxicam | Musculoskeletal and Joint Diseases | No data available |
|
Lornoxicam 8mg tablets
1001010AIAAACAC
|
Lornoxicam | Lornoxicam | Musculoskeletal and Joint Diseases | No data available |
|
Lumiracoxib 100mg tablets
1001010ANAAAAAA
|
Lumiracoxib | Lumiracoxib | Musculoskeletal and Joint Diseases | No data available |
|
Lumiracoxib 400mg tablets
1001010ANAAABAB
|
Lumiracoxib | Lumiracoxib | Musculoskeletal and Joint Diseases | No data available |
|
Mandafen 400mg tablets
1001010J0CYABAE
|
Mandafen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Mandafen 600mg tablets
1001010J0CYACAF
|
Mandafen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Mandafen for Children 100mg/5ml oral suspension sugar free
1001010J0CYAABH
|
Mandafen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Manorfen 200mg tablets
1001010J0CTABAD
|
Manorfen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Manorfen 400mg tablets
1001010J0CTAAAE
|
Manorfen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Masidemen 50mg/200microgram gastro-resistant tablets
1001010C0CPAAAM
|
Masidemen | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Masidemen 75mg/200microgram gastro-resistant tablets
1001010C0CPABAX
|
Masidemen | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.